The recently established Endocrine and Neuroendocrine Tumor Program at the Montefiore Einstein Center for Cancer Care is the first of its kind in the New York metropolitan area and one of only a few in the country.
Our highly specialized team evaluates and treats all types and stages of endocrine and neuroendocrine tumors, both benign and malignant. These include tumors associated with the thyroid, parathyroid, adrenal glands, pituitary gland, pancreas and gastrointestinal tract (carcinoids). The program also focuses on patients with familial syndromes, such as von Hippel-Lindau, MEN-1, MEN-2 and SDH and offers genetic counseling, as well as opportunities to participate in clinical trials.
Advanced Treatment Options and Specialized Expertise
The Endocrine and Neuroendocrine Tumor Program offers the full spectrum of minimally invasive treatment options for these tumors. They encompass:
- Laparoscopic removal of adrenal glands
- Laparoscopic approaches to localization and management of pancreatic neuroendocrine tumors
- Directed parathyroidectomy
We also perform minimally invasive procedures to treat all types of functional and nonfunctional pancreatic tumors.
Thyroid cancer, the most common type of cancer associated with the endocrine glands and the fastest-growing cancer in incidence in the United States, is four times more common among women than men. Always at the forefront of cutting-edge solutions, our expert physicians have begun using robotic surgery for thyroid tumors and liver transplant for metastatic neuroendocrine tumors in the pancreas. Our Center for Cancer Care enrolls patients with this condition on the organ donation list. We also treat neuroendocrine tumors in the liver with advanced solutions such as radiofrequency ablation, as well as other regional therapy strategies.
The Montefiore Einstein Center for Cancer Care and its research partner, Albert Einstein Cancer Center, a National Cancer Institute-designated Cancer Center, are committed to developing new treatments and therapies for our patients through various research endeavors. Our team is at the forefront in developing approaches to treat these diseases. Our laboratory team is also studying tumors to identify controlling genes that may help us discover why these tumors metastasize and to predict their levels of aggression. Developing models of these tumors will help us continue to translate our findings into future treatment solutions and methods of prevention.